Amneal Pharmaceuticals, Inc. AMRX Other dosage forms — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported other dosage forms — net revenue of $46.61M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue decreased by 17.4% year-over-year, from $56.42M to $46.61M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s other dosage forms — net revenue has grown at a 6.4% compound annual growth rate (CAGR), from $209.41M to $252.42M.
- What does other dosage forms — net revenue mean?
- This metric represents the total net revenue generated from the sale of pharmaceutical products categorized under specialized or non-standard dosage forms within the company's generics portfolio. It reflects the market demand and commercial performance of these specific delivery systems, excluding returns, allowances, and discounts. Monitoring this revenue stream provides insight into the company's ability to diversify its product offerings beyond traditional oral solids and capture value in niche pharmaceutical segments.